Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024

The methicillin-resistant staphylococcus aureus (mrsa) drugs market has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth observed in the historical period can be attributed to concerns about antibiotic resistance, the prevalence of hospital-acquired infections, increased surgical procedures, a global rise in MRSA cases, and high mortality rates associated with MRSA infections.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The anticipated growth in the forecast period can be attributed to ongoing challenges related to antibiotic resistance, advancements in MRSA diagnostics, the global prevalence of healthcare-associated infections, increased emphasis on preventive measures in surgery, and the rise in community-acquired MRSA cases. Major trends expected in this forecast period include the exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, a focus on pediatric-specific formulations, and global health initiatives aimed at combatting antibiotic resistance.

The anticipated rise in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections is poised to drive the growth of the market for drugs targeting MRSA. MRSA infections result from Staphylococcus bacteria that exhibit resistance to certain antibiotics commonly used to treat standard staph infections. Effective treatment of MRSA infections requires drugs capable of eradicating and inhibiting the growth of MRSA bacteria in both humans and animals. Notably, hospital-acquired MRSA infections witnessed a 14% increase from 2020 to 2021, as reported by the Centers for Disease Control and Prevention in November 2022. Additionally, a December 2022 report by Statens Serum Institute highlighted an increase in community-acquired infections linked to hospital or nursing sector contact in the previous six months. This surge in MRSA prevalence is a driving force behind the growth of the MRSA drug market.

The aging population is expected to contribute to the expansion of the MRSA drugs market. Defined as individuals aged 65 and older, the elderly population is more susceptible to infections, including MRSA, due to compromised immune systems associated with aging. As people age, their immune systems become less effective at defending the body against infections, making bacterial infections such as MRSA more prevalent. According to the World Health Organization's October 2022 report, it is projected that by 2030, one in six people globally will be aged 60 or older. The proportion of the population aged 60 and over will increase from 1 billion in 2020 to 1.4 billion, reaching 2.1 billion by 2050. Consequently, the rise in MRSA infections among the elderly is contributing to the growth of the MRSA drugs market.

A prominent trend in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market is product innovation. Major companies in this market are actively pursuing innovative products to enhance efficacy and maintain a competitive market position. An example is Melinta Therapeutics LLC, which, in March 2021, announced FDA approval for Kimyrsa (oritavancin), the first one-hour infusion product prepared from a 1,200 mg vial. Kimyrsa is indicated for treating adult patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive microorganisms, including MRSA. The drug acts by inhibiting transpeptidation, transglycosylation, and disrupting cell membrane integrity.

A strategic focus for major companies in the MRSA drug market is conducting clinical trials to improve products and sustain market presence. Clinical trials play a crucial role in researching new treatments and their impact on human health outcomes. For instance, Scope Fluidics S.A., a Poland-based biotechnology company, successfully completed clinical trials in April 2021 for the rapid PCR|ONE genetic test designed to detect the MRSA/MSSA panel. This diagnostic tool is a significant advancement in the quick identification of Staphylococcus aureus infections.

In March 2021, the Biomedical Advanced Research and Development Authority (BARDA) announced a partnership with ContraFect Corporation to develop exebacase, a medication targeting MRSA. This collaboration aims to address secondary bacterial infections that exacerbate sepsis and complicate responses to public health emergencies and standard medical procedures.

Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., The Medicines Company, AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Absynth Biologics, AmpliPhi Biosciences Corporation, AstraZeneca plc, 3M Co., Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs include lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics containing both lipid and peptide components, and they act by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis. These drugs find applications in treating various indications such as skin infections, bone and joint infections, bacteremia, and infections in animals. Methicillin-resistant Staphylococcus aureus (MRSA) is categorized into hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA) types. The administration of these drugs can be through oral or parenteral routes and is utilized by various end users, including hospitals, clinics, research and academic institutes, among others.

The methicillin-resistant staphylococcus aureus drugs market research report provides methicillin-resistant staphylococcus aureus drugs market statistics, including methicillin-resistant staphylococcus aureus drugs industry global market size, regional shares, competitors with a methicillin-resistant staphylococcus aureus drugs market share, detailed methicillin-resistant staphylococcus aureus drugs market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus drugs industry. This methicillin-resistant staphylococcus aureus drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.